EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Ischemic colitis and immunosuppression. An experimental model



Ischemic colitis and immunosuppression. An experimental model



Diseases of the Colon and Rectum 29(2): 99-101



The incidence of ischemic colitis in renal transplant recipients approaches 1 percent. The mortality in these patients with ischemic colitis is nearly 70 percent. Immunosuppressive agents have been implicated in the development of ischemic colitis. To study the effect of immunosuppressive agents on ischemic colitis, a 4-cm segment of the colon was devascularized in 27 male Fischer rats. The animals were divided into one control and two treatment groups. One treatment group received methylprednisolone and the other, azathioprine, in doses similar to those of renal transplant recipients. Both experimental groups, either separately or combined, showed significantly greater areas of colonic ischemic changes than did the control group. This study demonstrates that systemic administration of immunosuppressive agents may augment the development of ischemic colitis.

(PDF emailed within 1 workday: $29.90)

Accession: 005758541

Download citation: RISBibTeXText

PMID: 3510838



Related references

The influence of uremia and immunosuppression on an animal model for ischemic colitis. Diseases of the Colon & Rectum 29(11): 724-727, 1986

Effect of sildenafil in an experimental model of ischemic colitis. Digestive Diseases and Sciences 54(2): 419-419, 2008

Paraoxonase and arylesterase activities, lipid profile, and oxidative damage in experimental ischemic colitis model. Gastroenterology Research and Practice 2012: 979506-979506, 2012

Development of colonic lesions caused by occlusion of paracolic marginal artery and/or vein--an experimental study using the model of ischemic colitis. Nihon Shokakibyo Gakkai Zasshi 90(8): 1672-1681, 1993

A study on ischemic lesion of the large intestine from the morphological viewpoint of the experimental ischemic colitis. Stomach & Intestine 28(9): 943-958, 1993

Ischemic disorders of the large intestine wall: ischemic colitis and proctitis. A clinical and experimental study. Chirurgie; Memoires de L'academie de Chirurgie 105(4): 297-314, 1979

Acetic acid-induced colitis in the rat: a reproducible experimental model for acute ulcerative colitis. European Surgical Research. Europaische Chirurgische Forschung. Recherches Chirurgicales Europeennes 24(4): 211-225, 1992

Live Combined Bacillus subtilis and Enterococcus faecium Ameliorate Murine Experimental Colitis by Immunosuppression. International Journal of Inflammation 2014: 878054-878054, 2014

Spontaneous chronic colitis in TCR alpha-mutant mice; an experimental model of human ulcerative colitis. International Reviews of Immunology 19(1): 123-138, 2000

A novel animal model of ulcerative colitis Elimination of IL-2R+ cells and a luminal irritant induces severe experimental colitis. Gastroenterology 106(4 SUPPL ): A682, 1994

Effect of Candida colonization on human ulcerative colitis and the healing of inflammatory changes of the colon in the experimental model of colitis ulcerosa. Journal of Physiology and Pharmacology 60(1): 107-118, 2009

Fulminant gangrenous ischemic colitis: is it the solely severe type of ischemic colitis?. International Journal of Colorectal Disease (): -, 2016

Experimental ischemic colitis in the dog. Animal models for intestinal disease: 161-180, 1985

Intestine-Specific Mttp Deletion Increases the Severity of Experimental Colitis and Leads to Greater Tumor Burden in a Model of Colitis Associated Cancer. Plos One 8(6): E67819-E67819, 2013

Immunosuppression with an interleukin-2 fusion protein leads to improved LV function in experimental ischemic cardiomyopathy. International Immunopharmacology 10(2): 207-212, 2010